BioGeometry and Sanyou Bio have jointly announced the signing of a strategic partnership agreement. China-based startup BioGeometry is a digital biology pioneer company that specialises in artificial intelligence (AI)-driven protein design and R&D platform.

On the other hand, US-based startup Sanyou Bio, with operations in China, is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs.

Both parties will leverage their respective expertise in generative AI technology and practical experience of drug development from target discovery to Investigational New Drug (IND) application, to create a next-generation antibody drug discovery platform driven by AIGC and jointly promote trilateral cooperation with leading innovative pharmaceutical companies or biotechs to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve global competitiveness.

In this strategic cooperation, Sanyou Bio will integrate BioGeometry's proprietary generative AI antibody design platform (GeoBiologics). Both parties will invest their respective advantageous resources, professional technologies and experiences to create an outstanding Dry-Wet antibody R&D platform by integrating BioGeometry's leading AI algorithm dry lab platform with Sanyou Bio's wet lab capabilities.

This platform will be utilised for the development of more large molecule drug pipelines and the incubation of innovative projects, paving the way for further market expansion.